Dr. Jose Miguel Lizcano de Vega

Institutions of which it is part

I am Professor (Full) of Biochemistry at UAB University. Since 2021, I lead the Laboratory of Protein Kinases and Cancer at VHIR. Our group investigates new cell signaling pathways that control the proliferation and survival of cancer cells. We collaborate with biopharmaceutical companies for the preclinical development of new anticancer drugs. We are interested in the role of the new MAP kinase ERK5 in cancer proliferation, and in modulation of autophagy and of stress of endoplasmic reticulum as new strategies to improve chemotherapy and immunotherapy treatments.

Curriculum

I graduated in Biochemistry at the Universitat Autònoma de Barcelona (UAB). After obtaining a PhD in Biochemistry and Molecular Biology (Neurochemistry) at the UAB, I made a first postdoctoral stay at the Department of Biochemistry at Trinity College Dublin (1995-96), working on Molecular Pharmacology. In 1998, I joined the MRC Protein Phosphorylation Unit (Dundee, UK), where I specialized in the study of protein kinases and cellular signaling, and in their alteration in diseases such as diabetes and cancer.

In 2004, I joined the Institute of Neurosciences UAB as a Ramón y Cajal researcher. Since 2005, I am Associate Professor at the UAB Department of Biochemistry of the Faculty of Medicine. I founded the Cell Signaling group, which studies the role of protein kinases in degenerative processes such as neurodegenerative diseases and cancer. Since 2010, my interest has focused on the study of cell signaling alterations in cancer, and on the preclinical development of new antitumor drugs. I have been vice-director of the Department of Biochemistry and director of the Biochemistry Unit of the Faculty of Medicine of the UAB.

In 2021 I joined the VHIR Institute, to lead the Laboratory of Protein Kinases and Cancer, which I combine with my teaching activity on the UAB campus. The ultimate goal of my research is to understand the biochemical basis of the tumor cell, in order to develop new molecular therapies that improve the survival and quality of life of cancer patients.
Jose Miguel Lizcano de Vega

Institutions

Vall Hebron Institut de Recerca

Head of group

Protein kinases in cancer research

Subscribe to our newsletters and be a part of Campus Life

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.